RESPONSE TO FDA COMMENTS ON INFORMATION REQUEST#41 RECEIVED ON DECEMBER 23, 2021

The Sponsor acknowledges INFORMATION REQUEST#41 dated 23 DECEMBER 2021 in (**BOLD**)

Product: COVID-19 Vaccine, mRNA (SPIKEVAX)

Subject: Lot Release Protocol Template

Our review of your August 16, 2021 submission (STN 125752/1) is ongoing. We have the following request for additional information regarding your Lot Release Protocol Template:

Please note, the page numbers referenced below are from Adobe page numbering of the LRP template submitted in 125752/0.36.

Page 1 of 1:

ITEM 1:

Please align the selection "For Surveillance" under "Reason for Submission" so that it matches the rest of the reasons. Also, please leave a space under the "For Licensing Action" that looks like this:

STN/Supp #:

This is where you will list the STN and the supplement number for future licensing action submissions.

Sponsor Response:

The Sponsor has aligned the header of the Spikevax Lot Release Protocol template (QC-OTH-0609) with the example provided by the Agency.

ITEM 2:

Please format the signature area at the bottom of page 1 as follows:

Signature: _____ Date: _____

Printed Name: _____

Title: _____

Please Note: A digital signature of the person responsible for signing the protocol is recommended. A handwritten signature and printed name are acceptable, but if a digital signature is used, the "Printed Name" can be deleted.

Sponsor Response:

The Sponsor has aligned the signature at the bottom of page 1 of the Spikevax Lot Release Protocol template with the example provided by the Agency.

ITEM 3:

Please add an area for the electronic protocol number. This will need to be entered when the protocol is submitted electronically.

Protocol #: _____

Note: The Product Release Branch (PRB), Division of Manufacturing and Product Quality (DMPQ) of OCBQ receives Drug Product lots and LRPs. These are submitted via an electronic gateway that is different from that used for electronic submissions to the product office. If you have not already done so, please contact Ms. Cheryl Hulme, PRB, DMPQ at Cheryl.Hulme@fda.hhs.gov to obtain information needed to access the gateway.

Sponsor Response:

The Sponsor has added an area for the electronic protocol number to page 1 in the header of the of the Spikevax Lot Release Protocol template aligned with the example provided by the Agency. The Sponsor acknowledges the different electronic gateway for DP lots and LRPs.

Pages 1 through 9 of 9:

ITEM 4:

Please format the information at the top left of each page to look like this:

cc: 125752_0/2256/FC

Lot Number: _____

Licensed Name of Product: COVID-19 Vaccine, mRNA

Note: Please include this information (the three lines) at the top left corner of every page in the protocol. The reason for submission should be documented on the first page only and no other pages.

Sponsor Response:

The Sponsor has aligned the format of the information at the top left of each page of the Spikevax Lot Release Protocol template with the example provided by the Agency.

Page 8 of 9:

ITEM 5:

As endotoxin results are reported as EU/mL, please keep units consistent with Table 1 (Page 4 of 9).

Sponsor Response:

The Sponsor has revised the Spikevax lot release protocol template as follows to ensure the endotoxin results are reported with units consistent with the test methods and acceptance criteria for CX-024414 mRNA and mRNA-1273 DP respectively:

- An additional Appendix (now Appendix 1) for Endotoxin test details was added to the Spikevax Lot release protocol template to report endotoxin test details for the CX-024414 mRNA with endotoxin result units to (b) (4) to align and be consistent with Table 1 CX-024414 method and acceptance criteria.

- The existing Appendix (now Appendix 2) for Endotoxin test details was revised to reflect test details for mRNA-1273 Drug Product and the endotoxin result units were revised to EU/mL to align and be consistent with Table 2 mRNA-1273 Drug Product method and acceptance criteria.

Page 9 of 9:

ITEM 6:

Please include the sterility test method (e.g., Membrane Filtration or Direct Inoculation).

Sponsor Response:

The Sponsor has added the sterility test method to the Spikevax Lot Release Protocol template Appendix 3 (Sterility Test Details) aligned with the example provided by the Agency.